

Women's Longevity Summit
The ovary is among the first organs to age, and its decline drives women’s risk of osteoporosis, cardiovascular disease and dementia. Yet no therapy exists to slow it.
Join age1 for an afternoon addressing the elephant in the room: what will it take to get the first ovarian aging therapy approved?
Speakers include:
Ben Swanson (Co-founder and CEO, Skeletalis)
Avery Klemmer (Thrive Capital)
Diana Laird (UCSF)
Kutluk Oktay (Yale School of Medicine)
Evan Sussman (Co-founder and CEO, Granata Bio)
Kara Goldman (Northwestern Medicine)
Juan Camilo Arjona Ferreira (Head of R&D and Chief Medical Officer, Organon)
Jamie Justice (XPRIZE)
…and more to be announced
We will be exploring:
which ovarian aging targets and modalities are ready for translation
downstream consequences of ovarian aging and menopause, across bone, heart and brain health
the clinical path: endpoints and trial designs that could get a preventive therapy approved
how to bridge gaps in the funding landscape, from venture and pharma to prizes and philanthropy
Apply promptly, as space is limited and registration requires approval. We welcome founders, researchers, clinicians, pharma leaders and investors working in women’s longevity.